Citadel Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-157,000
| Closed | -$3.37M | – | 13885 |
|
|
2026
Q1 | $3.37M | Hold |
157,000
| – | – | ﹤0.01% | 5028 |
|
|
2025
Q4 | $1.46M | Buy |
+157,000
| New | +$1.31M | ﹤0.01% | 6564 |
|
|
2025
Q3 | – | Sell |
-23,500
| Closed | -$153K | – | 12961 |
|
|
2025
Q2 | $153K | Sell |
23,500
-45,500
| -66% | -$313K | ﹤0.01% | 10940 |
|
|
2025
Q1 | $547K | Sell |
69,000
-13,000
| -16% | -$140K | ﹤0.01% | 8282 |
|
|
2024
Q4 | $1.04M | Buy |
82,000
+56,300
| +219% | +$783K | ﹤0.01% | 6927 |
|
|
2024
Q3 | $358K | Sell |
25,700
-20,500
| -44% | -$292K | ﹤0.01% | 8940 |
|
|
2024
Q2 | $637K | Buy |
46,200
+25,800
| +126% | +$377K | ﹤0.01% | 7548 |
|
|
2024
Q1 | $337K | Buy |
20,400
+5,200
| +34% | +$77.8K | ﹤0.01% | 9216 |
|
|
2023
Q4 | $222K | Sell |
15,200
-300
| -2% | -$3.64K | ﹤0.01% | 9739 |
|
|
2023
Q3 | $190K | Buy |
15,500
+2,300
| +17% | +$30K | ﹤0.01% | 9996 |
|
|
2023
Q2 | $158K | Sell |
13,200
-700
| -5% | -$9.14K | ﹤0.01% | 10262 |
|
|
2023
Q1 | $186K | Buy |
13,900
+8,100
| +140% | +$158K | ﹤0.01% | 10306 |
|
|
2022
Q4 | $125K | Sell |
5,800
-8,200
| -59% | -$168K | ﹤0.01% | 10884 |
|
|
2022
Q3 | $280K | Sell |
14,000
-7,000
| -33% | -$149K | ﹤0.01% | 9724 |
|
|
2022
Q2 | $376K | Buy |
+21,000
| New | +$217K | ﹤0.01% | 9281 |
|
Other funds holding DAWN
Citadel Advisors's DAWN Position: Q1 2026 in Review
Citadel Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 1,359,613 shares — an estimated $19.2M sold.
Citadel Advisors first reported a position in DAWN in Q1 2022 and held it in 16 quarters. The position peaked at $12.7M in Q4 2025. 208 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.
- Citadel Advisors reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 1,359,613 Day One Biopharmaceuticals shares in Q1 2026, an estimated $19.2M.
- Citadel Advisors first reported a position in Day One Biopharmaceuticals in Q1 2022 and held it in 16 quarters.
- Citadel Advisors's Day One Biopharmaceuticals position peaked at $12.7M in Q4 2025.
- 208 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.